NCT07205328View on ClinicalTrials.gov

A Clinical Trial of MT200605 for the Treatment of Acute Ischemic Stroke

PHASE2RecruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

June 30, 2026

Conditions
Acute Ischemic Stroke
Interventions
DRUG

MT200605

MT200605 is an agonist of the receptor tyrosine kinase B (TrkB) and can enhances ATP synthesis in the mitochondria of the striatum and bolsters antioxidant and free radical-scavenging capabilities.

DRUG

MT200605

MT200605 is an agonist of the receptor tyrosine kinase B (TrkB) and can enhances ATP synthesis in the mitochondria of the striatum and bolsters antioxidant and free radical-scavenging capabilities.

DRUG

MT200605

MT200605 is an agonist of the receptor tyrosine kinase B (TrkB) and can enhances ATP synthesis in the mitochondria of the striatum and bolsters antioxidant and free radical-scavenging capabilities.

DRUG

Placebo

The placebo does not contain any active ingredients.

Trial Locations (1)

100070

RECRUITING

BeiJing Tiantan Hospital, Beijing

All Listed Sponsors
lead

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

INDUSTRY